The aim of this observational study is to evaluate a dose fractionation scheme for APBI using external radiotherapy with modulated intensity technique (IMRT), with the possible impact on the quality of life of patients as it decreases the treatment number of sessions and improves the efficiency and accessibility.
≥ 45 years or 40-44 if there isn´t any other risk factor
Diagnosed with infiltrating ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS) and that have undergone conservative surgery without ganglionar involvement (pN0) of any histological degree except from invasive lobular carcinoma and with a size ≤ 3 cm.
Disease free margins (R0: > 2mm).
Positive and negative estrogen receptor tumors.
Multicentric and multifocal tumors, except from if it´s focal and the only risk factor.
Patients must not have undergone a neoadjuvant QT therapy.
Patients with BRCA positive mutation will be excluded.
Those patients unable or unsuitable to understand and accept the informed consent.